These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 33636339)
21. Point mutation P174L of the penA gene endowing ceftazidime resistance to Burkholderia pseudomallei in China. Tian S; Wu X; Liu L; Li A; Li X; Pei H; Wang Y; Dance DAB; Chen H; Xia Q Drug Resist Updat; 2024 Sep; 76():101121. PubMed ID: 39018660 [TBL] [Abstract][Full Text] [Related]
22. Epidemiological cut-off value of clinical isolates of Burkholderia pseudomallei from Northern Queensland to meropenem, ceftazidime, trimethoprim/sulfamethoxazole and doxycycline by the microbroth dilution method. Maloney S; Engler C; Norton R J Glob Antimicrob Resist; 2017 Sep; 10():291-294. PubMed ID: 28729203 [TBL] [Abstract][Full Text] [Related]
23. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. Sam IC; See KH; Puthucheary SD J Clin Microbiol; 2009 May; 47(5):1556-8. PubMed ID: 19297597 [TBL] [Abstract][Full Text] [Related]
24. In vitro antimicrobial susceptibility of clinical and environmental strains of Burkholderia pseudomallei from Brazil. Bandeira Tde J; Brilhante RS; Rocha MF; Moreira CA; Cordeiro Rde A; Ribeiro JF; Castelo-Branco Dde S; Sidrim JJ Int J Antimicrob Agents; 2013 Oct; 42(4):375-7. PubMed ID: 23993065 [No Abstract] [Full Text] [Related]
25. Phenotypic characterization of three clinical isolates of Burkholderia pseudomallei in Ceará, Brazil. Virginio CG; Teixeira MF; Frota CC; Café VS; Rocha MF; Sidrim JJ Mem Inst Oswaldo Cruz; 2006 Feb; 101(1):95-7. PubMed ID: 16699716 [TBL] [Abstract][Full Text] [Related]
26. Clinical Manifestations, Antimicrobial Drug Susceptibility Patterns, and Outcomes in Melioidosis Cases, India. Koshy M; Jagannati M; Ralph R; Victor P; David T; Sathyendra S; Veeraraghavan B; Varghese GM Emerg Infect Dis; 2019 Feb; 25(2):316-320. PubMed ID: 30666953 [TBL] [Abstract][Full Text] [Related]
27. Antimicrobial susceptibility and genetic characterisation of Burkholderia pseudomallei isolated from Malaysian patients. Khosravi Y; Vellasamy KM; Mariappan V; Ng SL; Vadivelu J ScientificWorldJournal; 2014; 2014():132971. PubMed ID: 25379514 [TBL] [Abstract][Full Text] [Related]
28. Case Series Study of Melioidosis, Colombia. Rodríguez JY; Morales-López SE; Rodríguez GJ; Álvarez-Moreno CA; Esquea K; Pinzon H; Ramirez LR; Moreno L; Ocampo W; Cepeda ML Emerg Infect Dis; 2019 Aug; 25(8):1531-4. PubMed ID: 31310232 [TBL] [Abstract][Full Text] [Related]
29. The antibiotics of choice for the treatment of melioidosis in Indian set up. Shaw T; Tellapragada C; Eshwara VK; Bhat HV; Mukhopadhyay C Indian J Med Microbiol; 2016; 34(3):353-4. PubMed ID: 27514960 [TBL] [Abstract][Full Text] [Related]
30. Evaluating New Compounds to Treat Ross BN; Myers JN; Muruato LA; Tapia D; Torres AG Front Cell Infect Microbiol; 2018; 8():210. PubMed ID: 30013953 [No Abstract] [Full Text] [Related]
31. [Problems of resistance of the causative agent of melioidosis to antibiotics]. Antonov IuV; Popovtseva LD; Iarulin RG; Iliukhin VI; Lozovaia NA; Farber SM; Knirel' IuA; Varbanets LD Antibiot Khimioter; 1991 Oct; 36(10):26-8. PubMed ID: 1725248 [TBL] [Abstract][Full Text] [Related]
32. Antimicrobial susceptibility of Burkholderia pseudomallei isolates in Northern Vietnam. Nhung PH; Van VH; Anh NQ; Phuong DM J Glob Antimicrob Resist; 2019 Sep; 18():34-36. PubMed ID: 30685463 [TBL] [Abstract][Full Text] [Related]
33. Activity of five fluoroquinolones against 71 isolates of Burkholderia pseudomallei. Ho PL; Cheung TK; Kinoshita R; Tse CW; Yuen KY; Chau PY J Antimicrob Chemother; 2002 Jun; 49(6):1042-4. PubMed ID: 12039903 [No Abstract] [Full Text] [Related]
34. Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. Harris P; Engler C; Norton R Int J Antimicrob Agents; 2011 Jun; 37(6):547-9. PubMed ID: 21481571 [TBL] [Abstract][Full Text] [Related]
35. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Jenney AW; Lum G; Fisher DA; Currie BJ Int J Antimicrob Agents; 2001 Feb; 17(2):109-13. PubMed ID: 11165114 [TBL] [Abstract][Full Text] [Related]
36. Development and validation of a triplex quantitative real-time PCR assay to detect efflux pump-mediated antibiotic resistance in Burkholderia pseudomallei. Webb JR; Price EP; Somprasong N; Schweizer HP; Baird RW; Currie BJ; Sarovich DS Future Microbiol; 2018 Sep; 13(12):1403-1418. PubMed ID: 30256166 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of bla(PenA) and bla(OXA) in Burkholderia pseudomallei Isolated from Patients at Sappasitthiprasong Hospital and Their Susceptibility to Ceftazidime and Carbapenems. Panya M; Thirat S; Wanram S; Panomket P; Nilsakul J J Med Assoc Thai; 2016 Jan; 99 Suppl 1():S12-6. PubMed ID: 26817233 [TBL] [Abstract][Full Text] [Related]
38. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. Sarovich DS; Price EP; Von Schulze AT; Cook JM; Mayo M; Watson LM; Richardson L; Seymour ML; Tuanyok A; Engelthaler DM; Pearson T; Peacock SJ; Currie BJ; Keim P; Wagner DM PLoS One; 2012; 7(2):e30789. PubMed ID: 22363490 [TBL] [Abstract][Full Text] [Related]